Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119310 | 0.91 | — | — | |
| SCHEMBL5118983 | 0.90 | — | — | |
| SCHEMBL5114531 | 0.90 | — | — | |
| SCHEMBL5110489 | 0.89 | KDM4E (0.30) | KDM4E | |
| SCHEMBL5110898 | 0.89 | ALDH1A1 (0.33) | ALDH1A1MAPT | |
| SCHEMBL5108595 | 0.89 | KDM4E (0.32) | KDM4EALDH1A1 | |
| SCHEMBL5105582 | 0.89 | — | — | |
| SCHEMBL14289577 | 0.88 | — | — | |
| SCHEMBL5112364 | 0.88 | — | — | |
| SCHEMBL5118965 | 0.87 | KDM4E (0.31) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004269-A1 | Pyrazolylmethy Heteroaryl Derivatives | NEUROGEN CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-20080004269-A1 | Pyrazolylmethy Heteroaryl Derivatives | NEUROGEN CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-20080004269-A1 | Pyrazolylmethy Heteroaryl Derivatives | NEUROGEN CORPORATION | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004269-A1 | Pyrazolylmethy Heteroaryl Derivatives | GABBR1, GABRR1, GABRR3 | PKM 943/4885KDM4E 2740/4885ALDH1A1 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.